Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound

Cambridge, Mass., June 17, 2003 Critical Therapeutics, Inc. (CTI), a private biopharmaceutical company developing novel therapeutic products for critical care medicine, today announced the initiation of a dose-escalating Phase I clinical trial of its ethyl pyruvate compound, CTI-01.

The primary aim of the trial is to determine the safety and tolerability of the anti-inflammatory compound over a range of doses in healthy volunteer subjects. The trial will be conducted at the Clinical Pharmacology Research Unit at Parexel, Northwick Park Hospital in the United Kingdom. CTI's Phase I trial marks the first time the compound will be administered intravenously to humans.

"This study encompasses the achievement of several milestones," said CTI President and CEO Paul Rubin, M.D. "It marks CTI's first clinical trial in the Company's brief history and is especially notable because CTI-01 was discovered by Mitch Fink M.D., one of the company's founders. The speed and efficiency which with which we have advanced CTI-01 into human trials reflects the dedication and initiative of our entire team."

CTI-01 is a cytoprotective compound that reduces vascular and organ damage following severe insults to the body such as surgical and non-surgical trauma, pancreatitis or overwhelming infection. The small molecule has demonstrated potent anti-inflammatory and tissue protection activity in multiple animal treatment models of disease including pancreatitis, vascular reperfusion injury, hepatitis and endotoxemia. CTI-01 has the potential to prevent and reverse complications in patients undergoing serious operations or multi-organ failure associated with life- threatening acute conditions including shock, myocardial infarction, acute pancreatitis, burns, stroke or acute drug allergies.

Approximately $180 billion is spent each year to treat patients with these life threatening conditions, according to a study conducted by researchers at the Universit

Contact: Scott Solomon
Sharon Merrill Associates, Inc.

Page: 1 2

Related biology news :

1. Critically endangered monkey species plummets more than 50 percent since 1994
2. Save The Tiger Fund announces alliance with the Critical Ecosystem Partnership Fund
3. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
4. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
5. Critical early-defense trigger in plants found
6. Critical therapeutics is awarded U.S. patents for methods to diagnose and treat inflammatory disease
7. Researchers, Regulators, Industry, Consumer Advocates Gather to Discuss Critical Issues Facing the Pharmaceutical Industry
8. Study Furthers Understanding Of Critical Alzheimers Disease Gene
9. Gene Once Thought To Program Ovarian Development Instead Found To Be Critical For Production Of Sperm
10. UF Researchers: Gene Therapy Replaces Critical Protein In Animal Model Of Often-Fatal Lung-Liver Disease
11. Columbia Researchers Synthesize Compound With Possible Link To MacularDegeneration; Work Is Critical To Pinpointing Causes Of Disease, Scientists Say

Post Your Comments:

(Date:2/13/2020)... , ... February 13, 2020 , ... Murrieta Genomics ... will be hosting a lunch and learn event on February 25th from 11:30 am ... researchers and interested members of the public are invited to attend this free event, ...
(Date:2/11/2020)... ... February 11, 2020 , ... Modality Solutions, ... its ISO 9001:2015 registration by certification body Intertek. Modality Solutions’ Quality Manager, Hannah ... revised all existing Standard Operating Procedures (SOPs) and created ten new SOPs. Anderson ...
(Date:2/7/2020)... ... , ... dicentra , a leading clinical research organization ... supplement industries, announces 2020 membership with the International Probiotics Association (“IPA”). , ... probiotics. We are thrilled to join our IPA member colleagues and bring sound ...
Breaking Biology News(10 mins):
(Date:2/13/2020)... ... 2020 , ... Arriello , a provider of market ... Vault Safety™ as part of the company’s continued growth in pharmacovigilance operations. ... safety information such as SUSARs and ICSRS, aggregate report production, signal management, and ...
(Date:2/5/2020)... ... , ... Rare Disease Day® , held the last day in February ... (NORD), to raise awareness amongst the general public and decision-makers about rare diseases and ... Mystery” rare disease series will be shining the light on Rare Disease ...
(Date:1/28/2020)... ... January 28, 2020 , ... Today, ... Kits . The new Salivary Total Human IgG Assay Kit exemplifies ... G in saliva, researchers can extend the accuracy and ease of use of ...
(Date:1/24/2020)... Calif. (PRWEB) , ... January 24, 2020 , ... ... launch of their RedySmart™ mass flow meters and controllers ideal for ... as an ideal upgrade to antiquated rotameters. These thermal instruments employ high-precision MEMS ...
Breaking Biology Technology:
Cached News: